High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated NSCLC. Whether EGFR mutated NSCLC with CNS metastases can benefit from first-line treatment of high-dose furmonertinib has not been reported. This study aims to investigate the efficacy and safety of high dose furmonertinib in first-line treatment of EGFR mutated NSCLC patiens.

Trial Details

NCT ID
NCT05379803
Phase
PHASE2
Sponsor
Hunan Province Tumor Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Furmonertinib
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Signed written informed consent before any study-related procedure.
  • Age ≥ 18 years.
  • ECOG PS of 0 to 1 at screening,and with no clinically significant deterioration in the previous 2 weeks.
  • Expected survival ≥12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →